Potential Role of NF-κB in Esophageal Adenocarcinoma: As an Emerging Molecular Target

Journal of Surgical Research

Volumn 153, Issue 1, 2009, Pages 172-180

  Abdel Latif, Mohamed M M ^a   Kelleher, Dermot ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

apoptosis; chemotherapy; cytokines; esophageal adenocarcinoma; NF B

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; BARRETT ESOPHAGUS; BILE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; GENE ACTIVATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

ADENOCARCINOMA; APOPTOSIS; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; INFLAMMATION; NF-KAPPA B; OXIDATIVE STRESS;

EID: 63649137892     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.12.755     Document Type: Review

References (58)

1. Pera M., Cameron A.J., Trastek V.F., et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 (1993) 510
2. Carton E., Mulligan E.D., Keeling P.W., et al. Specialized intestinal metaplasia: Analysis of prevalence, risk factors, and association with gastro-esophageal reflux disease. Br J Surg 87 (2000) 362
3. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825
4. Vaezi M.F., and Richter J.E. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 117 (1995) 699
5. Stamp D.H. Bile acids aided by acid suppression therapy may be associated with the development of esophageal cancers in westernized societies. Med Hypotheses 66 (2006) 154
6. Fitzgerald R.C., Omary M.B., and Triadafilopoulos G. Dynamic effects of acid on Barrett's oesophagus. An ex vivo proliferation and differentiation model. J Clin Invest 98 (1996) 2120
7. Sen R., and Baltimore D. Inducibility of κ immunoglobulin enhancer binding protein NF-κ B by a post-translational mechanism. Cell 47 (1986) 921
8. Neurath M.F., Becker C., and Barbulescu K. Role of NF-κB in immune and inflammatory responses in the gut. Gut 43 (1998) 856
9. Baeuerle P.A., and Baltimore D. NF-κB: Ten years after. Cell 87 (1996) 13
10. Baeuerle P.A., and Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 12 (1994) 141
11. Siebenlist U., Franzoso G., and Brown K. Structure, regulation, and function of NF-κ B. Annu Rev Cell Biol 10 (1994) 405
12. Chen Z., Hagler J., Palombella V.J., et al. Signal-induced site-specific phosphorylation targets I κ α to the ubiquitin-proteasome pathway. Genes Dev 9 (1995) 1586
13. Schmid R.M., and Alder G. NF-κB/Rel/IκB: Implications in gastrointestinal disease. Gastroenterology 118 (2000) 1208
14. Abdel-Latif M.M., O'Riordan J., Windle H.J., et al. NF-κB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239 (2004) 491
15. Konturek P.C., Nikiforuk A., Kania J., et al. Activation of NFκB represents the central event in the neoplastic progression associated with Barrett's esophagus: A possible link to the inflammation and overexpression of COX-2, PPARγ, and growth factors. Dig Dis Sci 49 (2004) 1075
16. Jenkins G.J., Harries K., Doak S.H., et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-κB and induces IL-8 expression in esophageal cells in vitro. Carcinogenesis 25 (2004) 317
17. Triadafilopoulos G. Acid and bile reflux in Barrett's esophagus: A tale of two evils. Gastroenterology 121 (2001) 1502
18. Lee J.S., Oh T.Y., Ahn B.O., et al. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett's esophagus: Clue for chemoprevention of esophageal carcinoma by antioxidants. Mutat Res 480-481 (2001) 189
19. Tselepis C., Perry I., Dawson C., et al. Tumor necrosis factor-α in Barrett's esophagus: A potential novel mechanism of action. Oncogene 21 (2002) 6071
20. Li J., Minnich D.J., Camp E.R., et al. Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-κB. J Surg Res 132 (2005) 112
21. Isomoto H., Saenko V.A., Kanazawa Y., et al. Enhanced expression of interleukin-8 and activation of nuclear factor κ-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol 99 (2004) 589
22. O'Riordan J.M., Abdel-Latif M.M., Ravi N., et al. Proinflammatory cytokine and nuclear factor κ-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100 (2005) 1257
23. Abdel-Latif M.M., O'Riordan J.M., Ravi N., Kelleher D., et al. Activated nuclear factor-κ B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis Esophagus 18 (2005) 246
24. Debruyne P.R., Witek M., Gong L., et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-κB and Cdx2 in human esophageal cells. Gastroenterology 130 (2006) 1191
25. Duggan S.P., Gallagher W.M., Fox E.J., et al. Low pH induces coordinate regulation of gene expression in esophageal cells. Carcinogenesis 27 (2006) 319
26. Nguyen D.M., Chen G.A., Reddy R., et al. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg 127 (2004) 365
27. Abdel-Latif M.M., Raouf A.A., Sabra K., et al. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 17 (2005) 539-549
28. Liu J.F., Jamieson G.G., Drew P.A., et al. Aspirin induces apoptosis in esophageal cancer cells by inhibiting the pathway of NF-κB downstream regulation of cyclooxygenase-2. ANZ J Surg 5 (2005) 1011
29. Izzo J.G., Malhotra U., Wu T.T., et al. Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24 (2006) 748
30. Greten F.R., Eckmann L., Greten T.F., et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285
31. Pikarsky E., Porat R.M., Stein I., et al. NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 431 (2004) 461
32. Luo J.L., Maeda S., Hsu L.C., et al. Inhibition of NFκB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6 (2004) 297
33. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118 (2000) 487
34. Souza R.H., Shewmake K., Beer D.G., et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60 (2000) 5767
35. Yang G.Z., Li L., Ding H.Y., et al. Cyclo-oxygenase-2 is overexpressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-κB: An immunohistochemical study. Exp Mol Pathol 79 (2005) 214
36. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18 (1999) 6853
37. Bash J., Zong W.X., and Gélinas C. c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol Cell Biol 17 (1997) 6526
38. Sheehy A.M., and Schlissel M.S. Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. J Biol Chem 274 (1999) 708
39. Uzzo R.G., Clark P.E., Rayman P., et al. Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 91 (1999) 718
40. Kyrgidis A., Kountouras J., Zavos C., et al. New molecular concepts of Barrett's esophagus: Clinical implications and biomarkers. J Surg Res 125 (2005) 189
41. McCabe M.L., and Dlamini Z. The molecular mechanisms of esophageal cancer. Int Immunopharmacol 5 (2005) 1113
42. Fitzgerald R.C., Onwuegbusi B.A., Bajaj-Elliott M., et al. Diversity in the esophageal phenotypic response to gastroesophageal reflux: Immunological determinants. Gut 50 (2002) 451
43. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., et al. Inflammatory gradient in Barrett's esophagus: Implications for disease complications. Gut 51 (2002) 316
44. Dvorakova K., Payne C.M., Ramsey L., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 10 (2004) 2020
45. Leu C.M., Wong F.H., Chang C., et al. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22 (2003) 7809
46. Raouf A.A., Evoy D.A., Carton E., et al. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 16 (2003) 17
47. Chatelain D., and Flejou J.F. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: Histological mapping and expression of p53, p21, and Bcl-2 oncoproteins. Virchows Arch 442 (2003) 18
48. Goldblum J.R., and Rice T.W. Bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Modern Pathol 8 (1995) 866
49. Nakanishi C., and Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5 (2005) 297
50. Das K.C., and White C.W. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J Biol Chem 272 (1997) 14914
51. Bentires-Alj M., Barbu V., Fillet M., et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 (2003) 90
52. Wang C.-Y., Mayo M.W., and Baldwin A.S. TNF-α and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274 (1996) 784
53. Izzo J.G., Correa A.M., Wu T.T., et al. Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5 (2006) 2844
54. Agarwal B., Swisher S.G., Ajani J., et al. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg 79 (2005) 1716
55. Xi H., Baldus S.E., Warnecke-Eberz U., et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11 (2005) 8341
56. Mirvish S.S. Effects of vitamin C and E on N-nitroso compound formation, carcinogenesis, and cancer. Cancer 58 Suppl 8 (1986) 1842
57. Fountoulakis A., Martin I.G., White K.L., et al. Plasma and esophageal mucosal levels of vitamin C: Role in the pathogenesis and neoplastic progression of Barrett's esophagus. Dig Dis Sci 49 (2004) 914
58. Yamamoto Y., and Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107 (2001) 135